Pdl biopharma, inc. (PDLI)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08
Revenues
Royalty revenues

-

-

-

-

-

-

-

-

351,641

343,475

305,049

278,713

Interest revenue

0

2,337

17,744

30,404

36,202

48,020

18,976

6,355

-

-

-

-

Product revenue

-

-

-

-

0

0

-

-

-

-

-

-

Licenses Revenue

-

-

-

-

723

575

1,500

0

10,400

1,500

13,135

15,483

Revenues

54,757

198,110

320,060

244,301

590,448

581,225

456,260

380,880

362,041

344,975

318,184

294,196

Cost, Amortization

6,306

15,831

24,689

12,028

-

-

-

-

-

-

-

-

Operating expenses
Cost of Revenue

53,619

48,460

30,537

4,065

0

0

-

-

0

-

-

-

Amortization of intangible assets

-

-

-

-

0

0

-

-

-

-

-

-

General and administrative

45,598

45,420

45,641

39,790

36,090

34,914

29,755

25,469

18,338

41,396

21,064

51,544

Selling and Marketing Expense

8,482

17,139

17,683

538

0

0

-

-

-

-

-

-

Research and Development Expense

7,308

2,955

7,381

3,820

0

0

-

-

-

-

-

-

Impairment of Intangible Assets, Finite-lived

22,490

152,330

0

0

-

-

-

-

-

-

-

-

Change in fair value of contingent consideration

0

-41,631

349

-3,716

0

0

-

-

-

-

-

-

Asset Impairment Charges

10,768

8,200

0

3,735

0

0

-

-

-

-

-

-

Acquisition-related costs

-

-

-

3,564

0

0

-

-

-

-

-

-

Gain (Loss) on Sale of Notes Receivable

-

-

-

-51,075

-3,979

0

0

-

-

-

-

-

Legal settlement

-

-

-

-

-

-

-

-

-

-92,500

-

-

Total operating expenses

154,571

248,704

126,280

114,899

40,069

34,914

29,755

-

18,338

133,896

21,064

51,544

Operating loss from continuing operations

-99,814

-50,594

193,780

129,402

550,379

546,311

426,505

355,411

343,703

211,079

297,120

242,652

Non-operating expense, net
Interest and other income, net

6,030

6,065

1,659

588

368

315

242

758

593

468

1,004

-

Interest expense

11,404

12,157

20,221

18,267

27,059

39,211

24,871

29,036

36,102

43,529

19,357

14,219

Unrealized Gain (Loss) on Investments

36,402

0

0

-

-

-

-

-

-

-

-

-

Gain (Loss) on Disposition of Assets

3,476

0

0

-

-

-

-

-

-

-

-

-

Business Combination, Bargain Purchase, Gain Recognized, Amount

0

0

9,309

0

0

-

-

-

-

-

-

-

Gain (Loss) on Investments

0

764

0

0

-

-

-

-

-

-

-

-

Gain (Loss) on Extinguishment of Debt

-8,430

0

0

-2,353

6,450

-6,143

0

0

-766

-17,648

1,518

-

Total non-operating expense, net

26,074

-5,328

-9,253

-20,032

-20,241

-45,039

-24,629

-28,278

-36,275

-60,709

-16,835

14,901

Loss from continuing operations before income taxes

-73,740

-55,922

184,527

109,370

530,138

501,272

401,876

327,133

307,428

150,370

280,285

243,334

Income tax benefit from continuing operations

-3,049

12,937

73,826

45,711

197,343

179,028

137,346

115,464

108,039

58,496

90,625

5,014

Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

-70,691

-68,859

110,701

63,659

332,795

322,244

-

-

-

-

-

-

Income from continuing operations

-

-

-

-

-

-

-

-

-

-

-

238,320

Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax

-

-

-

-

-

-

-

-

-

-

-

-162,684

Discontinued Operation, Tax Effect of Discontinued Operation

-

-

-

-

-

-

-

-

-

-

-

7,249

Net Income (Loss) Attributable to Noncontrolling Interest

-280

0

-47

53

0

0

-

-

-

-

-

-

Loss on discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-169,933

Net Income (Loss) Attributable to Parent

-70,411

-68,859

110,748

63,606

332,795

322,244

264,530

211,669

199,389

91,874

189,660

68,387

Income (Loss) from Continuing Operations, Per Basic Share

-

-

-

-

-

-

-

-

-

-

-

2.01

Earnings Per Share [Abstract]
Discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-1.43

Basic (in Dollars per Share)

-0.59

-0.47

0.71

0.39

2.04

2.04

1.89

1.52

1.43

0.73

1.59

0.58

Discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-1.01

Net income per diluted share (in Dollars per Share)

-0.59

-0.47

0.71

0.39

2.03

1.86

1.66

1.45

1.15

0.54

1.07

0.47

Income (Loss) from Continuing Operations, Per Diluted Share

-

-

-

-

-

-

-

-

-

-

-

1.48

Weighted average shares outstanding
Basic (in Shares)

118,631

145,669

155,394

163,805

163,386

158,224

139,842

139,711

139,663

126

119,402

118,728

Diluted (in Shares)

118,631

145,669

156,257

164,192

163,554

173,110

159,343

146,403

177,441

178

184,400

167,869

Cash dividends declared per common share (in Dollars per Share)

-

-

-

0.10

0.60

0.60

0.60

0.60

0.60

1.00

-

-

Product Revenue [Member]
Revenue from Contract with Customer, Including Assessed Tax

85,835

105,448

84,123

31,669

-

-

-

-

-

-

-

-

Queen et al. patents [Member]
Revenues

9

4,536

36,415

166,158

-

-

-

-

-

-

-

-

Acquired rights [Member]
Revenues

-31,042

85,256

162,327

16,196

-

-

-

-

-

-

-

-

License and other [Member]
Revenues

-45

533

19,451

-126

-

-

-

-

-

-

-

-